Quest Diagnostics Incorporated (DGX) earns a Roarable Rating of B+ (Buy) with 78/100 RQD Confidence. High-quality cash engine (33% profit margin, 10% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
As of 2026-11-02, Quest Diagnostics Incorporated (NYSE: DGX) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 78/100 at a spot price of $251.82 (-0.43% 1D, market cap $27.83B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 14/20. Across 1016 tracked Health Care issuers, DGX ranks #20 in composite RQD confidence.
Within the Health Care sector (Medical Specialities), DGX carries a Roarable B+ (78/100 RQD), trailing P/E of 28.1x, gross margin of 33.2%, and ROIC of 10.3%. By comparison, LH (Labcorp Holdings Inc.) holds a B grade (73/100 RQD, P/E 34.0x, ROIC 8.3%, cap $29.86B) and GH (Guardant Health Inc.) posts a D+ grade (53/100 RQD, P/E N/A, ROIC -17.4%, cap $24.87B). Among the 5-stock peer group, DGX leads on earnings multiple (28.1x) while ILMN leads on capital efficiency (18.2% ROIC).
Per DGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001022079), Quest Diagnostics Incorporated generated $11.04B in revenue (+11.8% YoY), $992.0M in net income, and $1.36B in free cash flow against $16.23B in total assets and $5.17B in total debt. Key quantitative strengths: Strong cash generator (33% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±5.9% realized swing band)
SEC XBRL FY 2025 (10-K): 12.3% FCF Margin ($1.36B FCF) & 33.2% Gross Margin
Cannibal Buyback (-1.80% YoY Shares) & executive Form 4 sales trim 6 pts from alignment
Even with a 78/100 (B+) score, DGX faces multiple-compression risk if 28.1x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Broader market pullbacks can still drag down strong stocks in the short run.
Dilution & Margin Drag: Cannibal Buyback (-1.80% YoY Shares) — any gross margin slip below 30.7% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($238.89) or 200D SMA ($212.78) invalidates the momentum regime and cuts Target Base ($274.48) toward Bear Floor ($206.49).
Quest Diagnostics Incorporated (DGX) slipped -0.43% to $251.82, trading at 94% of its 52-week range ($171.18 – $256.99). High-quality cash engine (33% profit margin, 10% return on capital) with steady institutional support.
Yahoo Finance Singapore report covering Quest Diagnostics Incorporated (DGX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Quest Diagnostics Incorporated (DGX) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Quest Diagnostics Incorporated (DGX) market action, institutional positioning, and fundamental catalysts.
www.debelegger.nl report covering Quest Diagnostics Incorporated (DGX) market action, institutional positioning, and fundamental catalysts.
StockInvest.us report covering Quest Diagnostics Incorporated (DGX) market action, institutional positioning, and fundamental catalysts.
marketscreener.com report covering Quest Diagnostics Incorporated (DGX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Quest Diagnostics Incorporated (DGX) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Quest Diagnostics Incorporated (DGX) market action, institutional positioning, and fundamental catalysts.
For questions about this article or underlying research, email help@trefis.com.
Ebay, Quest Diagnostics, Fastenal, Chubb trade in or around buy points after earnings. TG Therapeutics breaks out.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +11.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on DGX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for DGX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Quest Diagnostics Incorporated (DGX) ranks #20 by composite RQD confidence (78/100, grade B+) and #60 by equity capitalization ($27.83B). Within this direct 5-issuer industry benchmark cohort, DGX leads on earnings valuation at 28.1x trailing P/E, while ILMN leads on capital efficiency and profitability with 18.2% ROIC and 66.1% gross margin. DGX currently leads its immediate peer cohort in composite quantitative strength at 78/100 (B+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| DGX
ACTIVE
Quest Diagnostics Incorporated | B+ | 78/100 | 28.1x | 33.2% | 10.3% | -0.43% | $27.83B | Benchmark Subject |
| LH Labcorp Holdings Inc. | B | 73/100 | 34.0x | 28.8% | 8.3% | -1.84% | $29.86B | /lh-vs-dgx → |
| GH Guardant Health Inc. | D+ | 53/100 | — | 64.5% | -17.4% | -3.51% | $24.87B | /gh-vs-dgx → |
| CNC Centene Corporation | C | 63/100 | — | 8.1% | -31.0% | -0.25% | $33.97B | /cnc-vs-dgx → |
| ILMN Illumina Inc. | B+ | 77/100 | 51.5x | 66.1% | 18.2% | -18.64% | $43.80B | /ilmn-vs-dgx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Quest Diagnostics Incorporated (DGX) reported GAAP revenue of $11.04B (+11.8% vs. FY2024 revenue of $9.87B , and +19.3% cumulative change since FY2023) , GAAP net income of $992.0M, operating cash flow of $1.89B, and free cash flow of $1.36B (+49.5% YoY). On the balance sheet, DGX closed FY2025 with $16.23B in total assets against $5.17B in total debt (Altman Z-Score: 4.01, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $11.04B | $992.0M | $1.89B | $1.36B | $16.23B | $5.17B |
| FY2024 (FY) | 2024-12-31 | $9.87B | $871.0M | $1.33B | $909.0M | $16.15B | $5.62B |
| FY2023 (FY) | 2023-12-31 | $9.25B | $854.0M | $1.27B | $855.7M | $15.30B | $3.58B |
As of 2026-11-02, Quest Diagnostics Incorporated (NYSE: DGX) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 78/100 at a spot price of $251.82 (-0.43% 1D, market cap $27.83B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 14/20. Across 1016 tracked Health Care issuers, DGX ranks #20 in composite RQD confidence.
Within the Health Care sector (Medical Specialities), DGX carries a Roarable B+ (78/100 RQD), trailing P/E of 28.1x, gross margin of 33.2%, and ROIC of 10.3%. By comparison, LH (Labcorp Holdings Inc.) holds a B grade (73/100 RQD, P/E 34.0x, ROIC 8.3%, cap $29.86B) and GH (Guardant Health Inc.) posts a D+ grade (53/100 RQD, P/E N/A, ROIC -17.4%, cap $24.87B). Among the 5-stock peer group, DGX leads on earnings multiple (28.1x) while ILMN leads on capital efficiency (18.2% ROIC).
Per DGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001022079), Quest Diagnostics Incorporated generated $11.04B in revenue (+11.8% YoY), $992.0M in net income, and $1.36B in free cash flow against $16.23B in total assets and $5.17B in total debt. Key quantitative strengths: Strong cash generator (33% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
DGX last traded at $251.82 (-0.43% on volume of 919,987 shares), positioning the stock +5.41% above its 50-day simple moving average ($238.89) and +18.35% above its 200-day simple moving average ($212.78). Across its 52-week range of $171.18 to $256.99, DGX sits at the 94.0% percentile with a 14-day RSI of 69.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.9% ($236.96 to $266.68).
Why DGX Stock slipped -0.43% Today — RQD Quant Desk Flash. High-quality cash engine (33% profit margin, 10% return on capital) with steady institutional support.
Per the Roarable RQD rating, DGX scores 78 out of 100, earning a B+ grade and the verdict label "Roarable Buy — Very Good Cash & Smart-Money Inflow." The five pillars are: Fundamental Cash Engine at 16/20 (ROIC 10.3%; FCF yield 4.88%), Whale 13F Flow at 18/20 (institutional accumulation and options positioning), Insider Conviction at 14/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 14/20 (Beta 1.01; sector sensitivity), and Forensic Balance Sheet at 16/20 (Altman Z 4.01; Piotroski F 8/9; Debt/Equity 0.72).
For a prospective investor, the strongest pillar is institutional flow (18/20), which the rating frames as the main upside driver. The cash engine and balance sheet pillars (both 16/20) indicate a business generating cash with forensic metrics the rating characterizes as sound. The lowest-scoring pillars are insider conviction and macro regime fit (both 14/20), meaning insider signals and macro sensitivity contribute less to the overall score. Valuation is a tradeoff: per the market data, P/E (TTM) is 28.1 and forward P/E is 26.1, which are elevated relative to the FCF yield of 4.88%. The rating's cash-based case therefore depends on continued earnings and cash growth to support the current multiple. This is an analytical summary of the rating, not personalized financial advice.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $11035.0M | $1556.0M | $992.0M | N/A | $1359.0M | $420.0M | $5167.0M |
| FY 2024 | $9872.0M | $1346.0M | $871.0M | N/A | $909.0M | $549.0M | $5615.0M |
| FY 2023 | $9252.0M | $1262.0M | $854.0M | N/A | $855.7M | N/A | $3581.2M |
Per the market data, gross margin is 33.2%, operating margin is 14.1%, and net margin is 9%, with ROIC at 10.3%. Per the Roarable RQD rating, the Altman Z-Score is 4.01, the Piotroski F-Score is 8/9, and Debt/Equity is 0.72. Revenue, operating income, and net income each rose across the three reported periods in the SEC financials. Debt was $5615.0M in FY 2024 and $5167.0M in FY 2025, while cash was $549.0M and $420.0M in those years respectively.
Per the recent news and catalysts section, six items reference DGX. The headlines reference a Q3 earnings release, with one item reporting "Q3 Adjusted EPS $3.00 per Share, vs. FactSet Est of $2.87." One Seeking Alpha item is headlined "Quest Diagnostics Upgraded After Strong Q3, While Also Announcing New Test For Alzheimer's" and carries a GREEN light and CATALYST impact label. The remaining items carry YELLOW lights and MARKET WIRE labels. Risk watch items are not separately identified in the source data beyond the general market-wire classification. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.
Real-time company headlines, analyst actions, and sector developments for Quest Diagnostics Incorporated (DGX) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance Singapore report covering Quest Diagnostics Incorporated (DGX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Quest Diagnostics Incorporated (DGX) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Quest Diagnostics Incorporated (DGX) market action, institutional positioning, and fundamental catalysts.
www.debelegger.nl report covering Quest Diagnostics Incorporated (DGX) market action, institutional positioning, and fundamental catalysts.
StockInvest.us report covering Quest Diagnostics Incorporated (DGX) market action, institutional positioning, and fundamental catalysts.
marketscreener.com report covering Quest Diagnostics Incorporated (DGX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Quest Diagnostics Incorporated (DGX) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Quest Diagnostics Incorporated (DGX) market action, institutional positioning, and fundamental catalysts.
Welcome to the DGX (Quest Diagnostics Incorporated) Roar Pit. Current RQD Composite is 78/100 (Roarable Buy — Very Good Cash & Smart-Money Inflow) in Medical Specialities. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on DGX, but look at what you are paying: 28.1x trailing P/E with 33.2% gross margins. Unless Quest Diagnostics Incorporated expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on DGX, the market is fixating on short-term headline noise in Medical Specialities and ignoring the balance sheet and cash flow trajectory. At $252.92 (52-wk range $171.18 - $256.99), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).